New testing strategy can speed up COVID-19 test results for healthcare workers

Fast turnaround of COVID-19 test results for healthcare workers is critical. Investigators have now developed a COVID-19 testing strategy that maximizes the proportion of negative results after a single round of testing, allowing prompt notification of results. The method also reduces the need for increasingly limited test reagents, as fewer additional tests are required. Their strategy is described in The Journal of Molecular Diagnostics, published by Elsevier.

There is an urgent need to reduce the spread of COVID-19 transmission in hospitals and care facilities and to maintain adequate levels of staffing. Group testing strategies with pooled samples have been proposed to increase capacity; however, the currently used strategies are slow.

“One of the main hurdles to initiating a comprehensive hospital staff testing program is the large number of staff requiring testing and the rapid turnaround times that would be required to make any screening strategy successful,” explained lead investigators Graeme Black, DPhil, and John Henry McDermott, MD, both from the Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK. “Using the method we have developed, any laboratory could adapt their testing scheme based on the current throughput and the current prevalence of infection in the population, facilitating a data-driven testing strategy.”

Traditional Dorfman sequential (DS) pooling combines multiple samples and, if a pool test returns positive, all of the constituent samples undergo further testing. In a healthcare setting, this means that even individuals who ultimately test negative for COVID-19 will have to isolate. The investigators developed a nonadaptive combinatorial (NAC) pooling approach that tests the same sample in several simultaneously assayed pools. The algorithm assumes initially that each sample is positive. It then attempts to disprove this assumption by finding a well in which the sample has been placed that has tested as negative. Then another algorithm is used to find positive wells that contain a single sample on the list of the remaining potentially positive samples. Indeterminate samples are retested.

To establish a suitable limit of detection for pooling, nasopharyngeal samples of known SARS-CoV-2 status were placed in two pools, each containing 14 SARS-CoV-2 negative samples and one SARS-CoV-2 positive sample, with the positive samples at differing viral loads. Pooling matrices were generated for 700, 350, and 250 samples, with each sample assigned to 2, 4, and 5 wells, respectively. The samples were also tested in a DS testing scheme. The efficacy of each matrix was tested under different SARS-CoV-2 prevalence levels of 0.1%, 3%, 7%, and 10% of the population.

All NAC matrices performed well at low prevalence levels, with an average of 585 tests saved per assay in the 700 sample matrix. In simulations of low-to-medium prevalence levels (0.1% – 3%), which is the prevalence expected in an asymptomatic healthcare worker population, all the NAC matrices required fewer retests than the DS testing scheme. However, as the population prevalence increased, the performance of each matrix deteriorated.

“Pooling becomes increasingly useful as the population prevalence of SARS-CoV-2 decreases,” Prof. Black and Dr. McDermott observed. “Initially the most conservative matrix, 250 samples, should be used to determine the prevalence level. As the prevalence falls, the use of less tolerant but higher throughput assays could be used, such as the 700 sample pool.”

The matrices and system to decode the results are freely available (www.samplepooling.com) and laboratories can choose the matrix that best suits their current population prevalence and sample size, facilitating a context-specific, relatively low cost data-driven testing approach.

“Many high-throughput testing schemes for SARS-CoV-2 detection have been developed over the past year. We illustrate the potential power that adaptable automated, innovative mathematical approaches have to increase COVID-19 diagnostic capability in a safe manner. Such an approach could reach far greater numbers, save lives, and be delivered in a sustainable way. Undoubtedly, this has considerable relevance to other future population-based screening approaches,” Prof. Black and Dr. McDermott concluded.

---

Notes
The article is “A Nonadaptive Combinatorial Group Testing Strategy to Facilitate Health Care Worker Screening during the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Outbreak,” by John H. McDermott, Duncan Stoddard, Peter J. Woolf, Jamie M. Ellingford, David Gokhale, Algy Taylor, Leigh A.M. Demain, William G. Newman, and Graeme Black (https://doi.org/10.1016/j.jmoldx.2021.01.010). It appears online in advance of The Journal of Molecular Diagnostics, volume 23, issue 5 (May 2021) published by Elsevier.

The article is openly available at https://www.jmdjournal.org/article/S1525-1578(21)00031-3/fulltext.

Elsevier’s Novel Coronavirus Information Center provides expert-curated information for researchers, healthcare professionals and public health officials, including clinical guidance and a portal to access all of Elsevier’s COVID-19 research. All resources are freely available. We also have dedicated hubs for healthcare professionals; health educators and students; librarians; and R&D professionals. You can find these in our Coronavirus Resource Directory.

About The Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.org

About Elsevier
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray’s Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com.